article thumbnail

Vertex signs licence deal with CRISPR Therapeutics for diabetes therapies

Pharmaceutical Technology

The system comprises the Cas9 enzyme and a guide RNA. Vertex Pharmaceuticals Cell and Genetic Therapies chief and executive vice-president Bastiano Sanna said: “We have multiple programmes in our T1D portfolio including VX-880 and VX-264, which are in the clinic, as well as our hypoimmune programme, in preclinical development.

article thumbnail

Scientists engineer safe, virus-resistant E coli for research

Drug Discovery World

In a step forward for genetic engineering and synthetic biology, US researchers have modified E coli bacteria to be immune to infection by all natural viruses tested so far. Genetic engineering The findings build on earlier efforts by genetic engineers, which involved genetically reprogramming E.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Alnylam finds belly fat gene and drug target in UK Biobank study

pharmaphorum

The RNA interference specialist says its researchers and collaborators have identified mutations in a gene called INHBE that are associated with protection against abdominal obesity and metabolic syndrome – a condition impacting more than 20% of adults worldwide.

article thumbnail

The challenges and trends of cell & gene therapies 

Drug Discovery World

However, whilst these comments largely reflect a positive outlook for investment in the industry, financing in Q1 of 2022 largely remained level with the backend of last year, hovering just over $500 million according to American Society of Gene & Cell Therapy’s (ASGCT) – Gene, Cell, & RNA Therapy Landscape Q1 report. .